Last reviewed · How we verify

ZD1839 (Gefitinib) — Competitive Intelligence Brief

ZD1839 (Gefitinib) (ZD1839 (Gefitinib)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: EGFR tyrosine kinase inhibitor. Area: Oncology.

phase 3 EGFR tyrosine kinase inhibitor EGFR Oncology Small molecule Live · refreshed every 30 min

Target snapshot

ZD1839 (Gefitinib) (ZD1839 (Gefitinib)) — AstraZeneca. ZD1839 (Gefitinib) is a small molecule that inhibits the epidermal growth factor receptor (EGFR) tyrosine kinase.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
ZD1839 (Gefitinib) TARGET ZD1839 (Gefitinib) AstraZeneca phase 3 EGFR tyrosine kinase inhibitor EGFR
Rybrevant AMIVANTAMAB Johnson & Johnson marketed EGFR, MET 2021-01-01
NERATINIB NERATINIB marketed EGFR, HER2, HER4 2017-01-01
Inlyta Axitinib Pfizer marketed Receptor tyrosine kinase inhibitor Vascular endothelial growth factor receptors (VEGFR)-1, VEGFR-2, VEGFR-3 2012-01-01
PONATINIB HYDROCHLORIDE PONATINIB HYDROCHLORIDE marketed ABL, T315I mutant ABL, VEGFR, PDGFR, FGFR, EPH receptors, SRC family, KIT, RET, TIE2, FLT3 2012-01-01
REGORAFENIB REGORAFENIB marketed RET, VEGFR1, VEGFR2, VEGFR3, KIT, PDGFR-alpha, PDGFR-beta, FGFR1, FGFR2, TIE2, DDR2, TrkA, Eph2A, RAF-1, BRAF, BRAF V600E, SAPK2, PTK5, Abl, CSF1R 2012-01-01
PAZOPANIB HYDROCHLORIDE PAZOPANIB HYDROCHLORIDE marketed VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-α, PDGFR-β, FGFR-1, FGFR-3, Kit, Itk, Lck, c-Fms 2009-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (EGFR tyrosine kinase inhibitor class)

  1. Betta Pharmaceuticals Co., Ltd. · 4 drugs in this class
  2. Hangzhou ACEA Pharmaceutical Research Co., Ltd. · 2 drugs in this class
  3. Genentech, Inc. · 2 drugs in this class
  4. AstraZeneca · 2 drugs in this class
  5. Millennium Pharmaceuticals, Inc. · 1 drug in this class
  6. Pfizer · 1 drug in this class
  7. Sichuan Cancer Hospital and Research Institute · 1 drug in this class
  8. Sun Yat-sen University · 1 drug in this class
  9. University of Chicago · 1 drug in this class
  10. Xinqiao Hospital of Chongqing · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ZD1839 (Gefitinib) — Competitive Intelligence Brief. https://druglandscape.com/ci/zd1839-gefitinib. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: